

157
Ced

2. **(Twice Amended)** The therapeutic agent composition for the corneal epithelial disorder as claimed in claim 1, wherein the compound having the effect of activating Rho is lysophosphatidic acid or an acyl derivative thereof.

3. **(Twice Amended)** The therapeutic agent composition for the corneal epithelial disorder as claimed in claim 2, wherein said compound having the effect of activating Rho is oleyl lysophosphatidic acid.

4. **(Twice Amended)** The therapeutic agent composition for the corneal epithelial disorder as claimed in claim 1, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

B2

6. **(Amended)** The therapeutic agent composition for the corneal epithelial disorder as claimed in claim 2, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

7. **(Amended)** The therapeutic agent composition for the corneal epithelial disorder as claimed in claim 3, wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

B2
cost

8. (Amended) A method of treating a corneal epithelial disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound having an effect of activating Rho.

B3

11. (Amended) The method as claimed in claim 8, wherein the corneal epithelial disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

12. (Amended) The method as claimed in claim 9, wherein the corneal epithelial disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

13. (Amended) The method as claimed in claim 10, wherein the corneal epithelial disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

Please add the following new claims:

B4

--14. (New) The method as claimed in claim 8, wherein the compound is administered in the form of eyedrops.

15. (New) The method as claimed in claim 14, wherein the eyedrops are instilled once to several times a day in a concentration of 0.0001 to 1% (w/v) solution.

16. (New) The method as claimed in claim 15, wherein the concentration is 0.001 to 1% (w/v) solution.

134
cont 17. (New) The method as claimed in claim 8, wherein the compound is orally administered in a daily dosage of 0.1 to 5000 mg.

18. (New) The method as claimed in claim 17, wherein the daily dosage is 1 to 1000 mg.--
